|
Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development |
|
Big Pharma’s 2012 colossal patent cliff looms. Thirteen blockbuster drugs are set to lose US patent protection; costing industry 70% in lost revenues. Furthermore, despite record R&D investment, biopharmaceutical productivity remains in decline.
|
|
Read more...
|
|
|
The Prescribing Data Restriction Program: Critical Assessment & Best Practices |
|
Since the mid-1990s, pharma companies have devised their sales and marketing strategies based on Rx data. However, with the introduction of the AMA’s Prescribing Data Restriction Program (PDRP) opt-out program in July 2006, pharma companies need to evaluate the impact of PDRP violation, mediate their PDRP compliance strategies, and revisit their existing Sales Force Effectiveness (SFE) practices.
|
|
Read more...
|
|
Evidence-Based Medicine: Current Use and Future Impact on Global Clinical and Reimbursement Practices |
|
Evidence-based medicine is defined as an attempt to use standards from scientifically-collected evidence to improve medical practices by assessing risks and benefits of treatments and/or the lack of treatments.
|
|
Read more...
|
|
|
|
|
